{"id":1528,"date":"2024-08-20T13:34:05","date_gmt":"2024-08-20T12:34:05","guid":{"rendered":"https:\/\/heliusstudy.nl\/?post_type=publicatie&#038;p=1528"},"modified":"2024-08-20T13:34:06","modified_gmt":"2024-08-20T12:34:06","slug":"unexploited-potential-of-risk-factor-treatment-in-patients-with-atherosclerotic-cardiovascular-disease","status":"publish","type":"publicatie","link":"https:\/\/heliusstudy.nl\/tr\/publicatie\/unexploited-potential-of-risk-factor-treatment-in-patients-with-atherosclerotic-cardiovascular-disease\/","title":{"rendered":"Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease"},"content":{"rendered":"\n<p><strong>Background:&nbsp;<\/strong>Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control.<\/p>\n\n\n\n<p><strong>Aims:&nbsp;<\/strong>This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event.<\/p>\n\n\n\n<p><strong>Methods and results:&nbsp;<\/strong>Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged \u226545 years at \u22656 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had \u22651 drug-modifiable risk factor not on target. Furthermore, 91% had \u22651 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years.<\/p>\n\n\n\n<p><strong>Conclusions:&nbsp;<\/strong>Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Background:&nbsp;Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. Aims:&nbsp;This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. Methods and results:&nbsp;Pooled data from [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"publications_year":[22],"thema":[42],"class_list":["post-1528","publicatie","type-publicatie","status-publish","hentry","publications_year-22","thema-cardiovascular-disease"],"acf":[],"_links":{"self":[{"href":"https:\/\/heliusstudy.nl\/tr\/wp-json\/wp\/v2\/publicatie\/1528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heliusstudy.nl\/tr\/wp-json\/wp\/v2\/publicatie"}],"about":[{"href":"https:\/\/heliusstudy.nl\/tr\/wp-json\/wp\/v2\/types\/publicatie"}],"wp:attachment":[{"href":"https:\/\/heliusstudy.nl\/tr\/wp-json\/wp\/v2\/media?parent=1528"}],"wp:term":[{"taxonomy":"publications_year","embeddable":true,"href":"https:\/\/heliusstudy.nl\/tr\/wp-json\/wp\/v2\/publications_year?post=1528"},{"taxonomy":"thema","embeddable":true,"href":"https:\/\/heliusstudy.nl\/tr\/wp-json\/wp\/v2\/thema?post=1528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}